The Regener8 Annual Meeting will feature Professor Anthony Hollander, part of the team that successfully created and transplanted the first ever tissue-engineered windpipe, and John Ferris, from Cytori Therapeutics, a leading company in the development of cell therapies based on autologous adipose-derived cells.
Focusing on ‘The Delivery of Regenerative Medicine: Getting Regenerative Therapies to the Patient and the Market’, the Regner8 Annual Meeting is now in its eighth year and as a key component of MEIbioeng15, will form part of the UK’s largest gathering of biomedical engineers, bioengineers and medical engineers. The Regener8 event will also attract delegates interested in nanotechnology, biomaterials and tissue engineering.
Professor Anthony Hollander is a stem cell researcher with more than 20 years of research experience in the fields of cartilage biology, osteoarthritis, stem cells and tissue engineering. He currently heads the University of Liverpool’s Institute of Integrative Biology, prior to which he was head of the School of Cellular and Molecular Medicine at the University of Bristol.
In his early career, Professor Hollander spent three years at the internationally renowned cartilage laboratory at McGill University in Montreal, then returned to the UK to take up an Arthritis Research UK fellowship and a lectureship at the University of Sheffield. In 2000 he was appointed to the Chair of Rheumatology & Tissue Engineering at The University of Bristol – the first time that a non-clinical scientist had been appointed to a Chair of Rheumatology in the UK.
He has more than 100 publications, has secured £7 million of peer-reviewed funding over the past 10 years, and has several patents in his name. He is co-founder and scientific director of a University of Bristol spin-out company, Azellon Cell Therapeutics and in 2010 was ranked among the top 40 scientists in Britain by The Times.
Professor Hollander’s keynote address will include a case study of Azellon’s Cell Bandage technology, which uses a patient’s own stem cells as an internal ‘bandage’ to encourage cell growth and allow tears to repair. He is confident the Cell Bandage will promote better short-term recovery for meniscal tears, prevent or delate osteoarthritis in damaged knees and potentially treat a wide range of other injuries. In 2013 the Cell Bandage began its first clinical trial, with positive results so far.
John Ferris, meanwhile, will be speaking on ‘Challenges in Commercialising Regenerative Medicine’. John has been the European Director for San Diego-based Cytori Therapeutics for nearly ten years. Cytori develops and manufactures medical devices that enable the therapeutic use of the adult stem and regenerative cells naturally found within adipose tissue.
John’s main responsibilities include the commercialisation of Cytori’s Celution® system for the isolation and concentration of adipose-derived regenerative cells. The Celution system is CE marked for use in a wide range of clinical indications including plastic and reconstructive surgery, wound healing and the treatment of soft tissue wasting disorders.
His keynote will discuss the role of cell therapies in delivering the next generation of healthcare and how companies entering this sector must learn to navigate a landscape which seems to be beset with challenges in every direction.
John has vast industry experience spanning more than 30 years. His career includes roles as Business Development Director at Cardiologic, Managing Director (Europe) of MacroPore Biosurgery, European Business Development Director at Norian Corporation, Director of Marketing at DePuy Orthopaedics and Product Manager at Thackray Orthopaedic.
For more information on the The Regener8 Annual Meeting and MEIbioeng15, visit http://meibioeng.org.